{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Severity of AECOPD, overall and by GOLD grade, over the course of 1 year.', 'Duration of AECOPD, overall and by AECOPD severity, over the course of 1 year.', 'FEV1% of predicted normal value in stable COPD patients, at Pre-Month 0 and', 'Month 12.', 'Healthcare utilisation for COPD, over the course of 1 year.', 'Tertiary endpoints', 'Bacterial load measured by both culture and PCR in COPD and during AECOPD.', 'Viral load measured by PCR in COPD and during AECOPD.', 'Section 9.5 Analysis of primary objective', 'The proportion of sputum samples obtained at each visit (confirmed stable visits and', 'AECOPD visits [any severity, mild, moderate and severe]) and positive for specific', 'bacterial/viral pathogens by bacteriological culture-methods and PCR, respectively', '(overall and by bacterial/viral species) will be computed with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled [stable] study visit for which', 'the investigator confirms in the eCRF that the subject is stable/ has recovered from a', 'previous exacerbation.', 'Section 9.6 Analysis of secondary objectives', 'The proportion of sputum samples obtained at each visit (confirmed stable visits* and', 'AECOPD visits [any severity, mild, moderate and severe]) and positive for specific', 'bacterial pathogens by both bacteriological methods and PCR (overall and by bacterial', 'species) will be computed with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled [stable]study visit for which', 'the investigator confirms in the eCRF that the subject is stable/has recovered from', 'a previous exacerbation.', 'The proportion of sputum samples obtained at each stable visit and positive for specific', 'bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and', 'by bacterial/viral species) will be computed with 95% confidence intervals, by GOLD', 'grade at enrolment.', 'The proportion of sputum samples obtained at each AECOPD visits and positive for', 'specific bacterial/ viral pathogens by bacteriological methods and PCR, respectively', '(overall and by bacterial/viral species) will be computed with 95% confidence intervals,', 'by AECOPD severity.', 'Those proportions will be also presented by GOLD grade at enrolment.', '19-OCT-2018', '99', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The following incidence rates will be computed, with 95% confidence intervals (CI):', 'All-cause AECOPD.', 'AECOPD having sputum containing bacterial pathogens found by PCR and or by', 'bacteriological methods or by both methods overall and by, but not limited to, the', 'following bacterial species: H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'and P. aeruginosa).', 'The 95% CI of the incidence rate will be computed using a model which accounts for', 'repeated events. The Generalised linear model assuming the Negative Binomial', 'distribution for the response variable with logarithm as link function, and the logarithm of', 'time for follow-up as an offset variable will be used. The incidence rates described above', 'will also be computed for mild, moderate AECOPD and for severe AECOPD and by', 'GOLD grade at enrolment and will be estimated by country.', 'Descriptive statistics (median, mean, range, standard deviation, first and third quartiles)', 'on the CAT and SGRQ-C scores will be tabulated at each respective visit.', 'Descriptive summaries on healthcare use for COPD will be provided.', 'Section 9.6 Analysis of tertiary objectives', 'Descriptive summaries of the quantity of specific bacteria at each scheduled [stable]', 'and exacerbation visit will be provided for both culture and PCR analysis.', 'Descriptive summaries of the quantity of specific viruses at each scheduled [stable] and', 'exacerbation visit will be provided for PCR analysis.', 'Section 9.8.1 Sequence of analyses', 'An interim analysis of the bacterial primary objective will be performed when by the', 'time of country allocation for the Phase 2 vaccine trial (provided that at least 4050', 'AECOPD sputum samples are available). The rate of positive samples will be', 'computed for Hi, NTHi and Mcat together and per pathogen. No study report will', 'be written at this stage.', 'A final analysis of all objectives will be performed after the last subject last visit of', 'the entire study. A final study report will be written at this stage.', 'Section 12 References', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for', 'the diagnosis, management, and prevention of Chronic Obstructive Pulmonary', 'Disease, updated 2017. Available from:', 'http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/', 'Guoping Hu, MD, PhD; Yumin Zhou, MD et al. Risk of COPD from Exposure to', 'Biomass Smoke: A Metaanalysis. CHEST. 2010; 138(1):20-31', '19-OCT-2018', '100', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}